Implementation of transmural disease management in patients admitted with advanced heart failure

Abstract

Objective The objective of this study was to assess the feasibility and impact on readmissions of transmural disease management across the borders of the cardiology department in patients with advanced heart failure (HF). Methods and resultsConsecutive patients, readmitted within one year for advanced HF by a dedicated specialist (n = 55), were followed for 22 ± 10 months after implementation of a hospitalwide transmural disease management strategy. Participants received a tag in their electronic medical record, triggering a HF caregiver contact, with subsequent guideline-recommended, protocol-driven care on each cardiac or non-cardiac hospitalization as well as outpatient evaluation. Upon transition to outpatient follow-up, patients were instructed to call the HF caregiver with any question at low threshold. Readmission rates were prospectively collected. Despite receiving adequate treatment with neurohumoral blockers, patients (71 ± 11 years; ejection fraction 35 ± 13%) had spent 4% (27%) of the year preceding study inclusion in hospital, with 73% admitted once, 20% twice, and 7% more than twice for acute decompensated HF (ADHF). During the study, patients were exposed to 6 ± 4 dedicated HF caregiver contacts. Participation in remote device monitoring increased from 31% to 92%, with 1 (0-3) additional phone contacts per patient-year of follow-up in this subgroup (n = 24). All-cause mortality and readmission rates for ADHF were 10% and 25% after one year, and 19% and 39% after 2 years, respectively. Follow-up time spent in hospital decreased signifi cantly to 2% (16%) (P value = 0.047).Conclusions Follow-up of advanced HF patients through transmural disease management is feasible and associated with favourable clinical outcome.Keywords Disease management -heart failure -hospitalization -quality of health care.

A Novel Intelligent Two-Way Communication System for Remote Heart Failure Medication Uptitration (the CardioCoach Study): Randomized Controlled Feasibility Trial

“…There is strong evidence that adherence to guidelines and optimal drug treatment leads to a better clinical outcome and reduced mortality and (re)hospitalizations [1]. HF disease management programs are widely used to facilitate the implementation of guideline-recommended treatment strategies [13-17]. Unfortunately, studies have proven that they are still insufficiently implemented in practice [15,18-20].…”

Heart rate reduction and exercise performance in recent onset heart failure with reduced ejection fraction: arguments for beta-blocker hypo-response

“…All patients included in a heart failure quality of care programme at this centre, from May 2009 until January 2013, were screened. A detailed description of the programme has been published before by our group 19 . Briefly, by means of a tag in the patient's electronic medical record, a dedicated heart failure nurse visit was triggered with each hospital readmission (including non-cardiac ward admissions) or outpatient evaluation.…”

Bioimpedance Alerts from Cardiovascular Implantable Electronic Devices: Observational Study of Diagnostic Relevance and Clinical Outcomes

“…In 2010, a dedicated remote follow-up program of heart failure patients with a CIED was started at Ziekenhuis Oost-Limburg (Genk, Belgium). Dedicated nurses, trained in electrophysiology, device follow-up, and heart failure pathophysiology, review all incoming alerts in a systematic and standardized manner with automatic interventions triggered by protocol-based, guideline-recommended care [ 13 , 14 ]. In this observational registry study, we closely analyzed all bioimpedance alerts and subsequent triggered interventions from OptiVol and OptiVol 2.0 (Medtronic PLC) and CorVue (St. Jude Medical LLC) CIEDs using the default alert settings, and we studied their impact on clinical outcome.…”